Biogen (BIIB) Total Current Liabilities (2009 - 2026)

Biogen's Total Current Liabilities history runs 18 years deep, the most recent figure standing at $3.0 billion for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 43.39% year-over-year to $3.0 billion; the TTM figure through Mar 2026 stood at $3.0 billion (down 43.39% YoY), while the FY2025 annual figure was $3.3 billion, down 39.42% from the prior year.
• Total Current Liabilities was $3.0 billion for Q1 2026 at Biogen, down from $3.3 billion in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $5.5 billion in Q4 2024 to a low of $3.0 billion in Q1 2026.
• Historically, Total Current Liabilities has averaged $3.9 billion across 5 years, with a median of $3.3 billion in 2025.
• The sharpest annual moves came in 2025 and 2026: Total Current Liabilities jumped 64.37% in 2025, then tumbled 43.39% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $3.3 billion in 2022, then increased by 4.93% to $3.4 billion in 2023, then jumped by 60.99% to $5.5 billion in 2024, then slumped by 39.42% to $3.3 billion in 2025, then decreased by 10.46% to $3.0 billion in 2026.
• The last three Total Current Liabilities figures came in at $3.0 billion (Q1 2026), $3.3 billion (Q4 2025), and $3.3 billion (Q3 2025), per Business Quant data.